Clinical trial NCT00596453: Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability
Official title: Impact of Antibiotic Treatment on PSA Variability
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Prostate Infections
Keywords: Prostate Specific Antigen (PSA)
Elevated Prostate Specific Antigen (PSA)
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
First posted: 2008-01-17
Enrollment: 31
Sex: MALE
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Ciprofloxacin hydrochloride has been approved by the Food and Drug Administration (FDA) for the treatment of mild to moderate infections, including prostate infections. It has been suggested that antibiotic treatment influences PSA levels due to the fact that an increase in PSA levels may be caused by inflammation or swelling of the prostate. Antibiotics are used to treat such inflammatory conditions. However, it has not been proven that antibiotics can be used to lower PSA. This research is being done to see if treatment with the antibiotic Ciprofloxacin hydrochloride affects the Prostate-Specific Antigen (PSA) blood test. This study may also help doctors in deciding which patients need a prostate biopsy.

Detailed description: This study is directed towards men who have been referred to the Urology clinic at the Johns Hopkins Outpatient Center in Baltimore, MD. If a patient fits the eligibility criteria and signs a consent form, the patient will have his blood drawn for the first PSA measurement. The patient must return to the Johns Hopkins Outpatient Center one week later for a second PSA measurement. The patient will be randomized to receive treatment with placebo or Ciprofloxacin hydrochloride for 14 days. The patient must return to the Johns Hopkins Outpatient Center at the end of the treatment cycle for the third PSA measurement. The patient will return one week later for his biopsy and fourth PSA measurement.

Eligibility criteria: Inclusion Criteria:

* Must be a patient of Johns Hopkins Urology Outpatient Clinic
* Must have an elevated PSA (\> 2.5 ng/mL) and be selected on the basis of a serum PSA evaluation for Transrectal Ultrasound (TRUS)/biopsy
* Must be able to understand and willing to adhere to the study protocol
* Must be willing to take the antibiotic or placebo for two weeks prior to the biopsy and agree to have the biopsy regardless of the change in PSA

Exclusion Criteria:

* Abnormal digital rectal examination
* Anyone currently being treated or who have been treated for any prostatic diseases (prostatitis, prostate Benign Prostatic Hyperplasia (BPH) surgery, prostate cancer) or urinary tract infection in the past
* Anyone taking medications that are likely to alter serum PSA concentration (specifically, androgen steroid hormones, antiandrogens, finasteride, Leutinizing Hormone Releasing Hormone (LHRH) analogues)
* Anyone unwilling to sign the informed consent or who are unlikely to adhere to the study protocol
* Anyone with a known allergy to fluoroquinolone antibiotics
* Anyone on blood thinning medication (Coumadin)
* Anyone taking Tizanidine
* Anyone with a history of seizures or cerebral arteriosclerosis
* Anyone who has taken an antibiotic medication within the past two weeks

Primary outcomes:
measure: PSA Levels (Change in PSA Levels With and Without Antibiotics Therapy)
timeFrame: 1 month post enrollment
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins Hospital Outpatient Center
state: Maryland
Study officials:
affiliation: Johns Hopkins University
name: Misop Han, M.D., M.S.
role: PRINCIPAL_INVESTIGATOR
References: